Sponsors Recommend Novotech for CRO Leadership Award
2018年8月9日 - 2:00PM
JCN Newswire
Asia-Pacific specialist CRO Novotech has been awarded the
"Exceeded Customer Expectations" Award by Life Science Leader
magazine based on findings from sponsor companies that utilise
outsourcing services. In particular, Novotech was recognised for
its local market/regulatory knowledge and for meeting timelines.
https://www.croleadershipawards.com/
As part of a 2018 review of the CRO industry from the biopharma
perspective, Life Science Leader selected Novotech as a leader in a
number of key categories including:
- Local market/regulatory knowledge
- Operational Excellence
- Scientific knowledge
- Therapeutic experience
- Study design expertise
- Responsiveness
- Data quality
- Meeting overall project timelines
According to Life Science Leader:
"The vetting process for selecting outsourcing partners is time
consuming and complex.
To support the process, Life Science Leader developed the CRO
Leadership Awards in 2012.
We think sponsor company opinions are important and credible -
that's why the awards are based on customer feedback.
Winning CROs are chosen through impartial market research based on
feedback from sponsor companies that utilize outsourcing
services.
Primary market research by Industry Standard Research (ISR) is the
basis of the awards.
Sponsors provide ratings of CROs based on recent outsourced
projects. This experiential feedback is analyzed by sponsor company
size to reveal leading CROs in different performance
categories."
Novotech CEO Dr John Moller said he was pleased Novotech was
recognised by the industry for its expertise, especially for
Asia-Pacific local market/regulatory knowledge.
"Novotech, known as the Asia-Pacific CRO, has offices and teams on
the ground as well as MOUs and long-term relationships with major
hospitals that directly benefit our clients."
"Our in-country relationships enable a more comprehensive
understanding of local regulatory changes, access to leading PIs,
strong site connections, and productive patient populations to
deliver success for our clients within timelines and budgets."
Novotech was established in 1996, headquartered in Australia with
offices in 11 countries across the region, and MOUs with major
health providers.
About Novotech - https://novotech-cro.com/welcome
Headquartered in Sydney, Novotech is internationally recognised as
the leading regional full-service contract research organisation
(CRO). With a focus on clinical monitoring, Novotech has been
instrumental in the success of hundreds of Phase I - IV clinical
trials in the Asia Pacific region.
Novotech provides clinical development services across all clinical
trial phases and therapeutic areas including: feasibility
assessments; ethics committee and regulatory submissions, data
management, statistical analysis, medical monitoring, safety
services, central lab services, report write-up to ICH
requirements, project and vendor management. Novotech's strong Asia
Pacific presence includes running clinical trials in all key
regional markets. Novotech also has worldwide reach through the
company's network of strategic partners.
For RFP enquiries: Please fill out the form available at
www.novotech-cro.com/contact-us-0
Media Contact
Susan Fitzpatrick-Napier
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Source: Novotech
Copyright 2018 JCN Newswire . All rights reserved.